GREY:DGCRF - Post by User
Comment by
bingostaron Feb 24, 2016 9:17am
182 Views
Post# 24588554
RE:SHAREHOLDERS WHO VOTES (YES) MUST NOT COMPLAIN
RE:SHAREHOLDERS WHO VOTES (YES) MUST NOT COMPLAINAeterna Zentaris Commences Promotional Activities for APIFINY Prostate Cancer Blood Test . Business Wire Aeterna Zentaris Inc. February 23, Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the Company) today announced that it has started promoting APIFINY, the only cancer specific, non-PSA blood test for the evaluation of the risk of prostate cancer, in 20 U.S. territories pursuant to its co-marketing agreement with Armune BioScience, Inc. Under the co-marketing agreement, the Company will promote APIFINY to designated medical professionals and will receive a commission for each test performed resulting from its targeted promotion. Jude Dinges, Senior Vice President and Chief Commercial Officer of Aeterna Zentaris, commented: Our sales force has initiated the promotion of APIFINY, the only cancer specific, non-PSA based blood test available today. Given its ability to measure the immune-system response to prostate cancer, we believe APIFINY represents an important addition to clinical information for patients and their clinicians pertaining to the risk assessment for prostate cancer.